ESR1 and breast carcinoma: To determine whether the synthesized compounds exerted anti-proliferative activity against breast cancer cells, we employed three well-established human breast cancer cell models representing distinct molecular subtypes: MCF-7 cells (estrogen receptor-positive, metastatic ductal carcinoma) and MDA-MB-231 cells (triple-negative, metastatic adenocarcinoma).